Optimization of the retention properties of vincristine in liposomal systems.

[1]  P. Cullis,et al.  Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. , 1993, Biochimica et biophysica acta.

[2]  E. Evans,et al.  Osmotic properties of large unilamellar vesicles prepared by extrusion. , 1993, Biophysical journal.

[3]  M. Bally,et al.  Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. , 1990, Cancer letters.

[4]  M. Bally,et al.  Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.

[5]  M. Bally,et al.  Liposomes with entrapped doxorubicin exhibit extended blood residence times. , 1990, Biochimica et biophysica acta.

[6]  M. Bally,et al.  Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. , 1990, Cancer research.

[7]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[8]  G. Scherphof,et al.  Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. , 1987, Biochimica et biophysica acta.

[9]  P S Schein,et al.  Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. , 1983, Cancer research.

[10]  Y. Barenholz,et al.  Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. , 1983, Cancer research.

[11]  Y. Barenholz,et al.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. , 1982, Cancer research.

[12]  P. Schein,et al.  Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. , 1982, Cancer research.

[13]  F. Szoka,et al.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.

[14]  C. Hunt,et al.  Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size. , 1979, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Tomowo Kobayashi,et al.  Enhancement of anti‐tumor activity of 1‐β‐d‐arabinofuranosylcytosine by encapsulation in liposomes , 1977 .

[16]  J. Fendler,et al.  Liposomes as drug carriers. , 1977, Life sciences.

[17]  P. Cullis,et al.  Uptake of basic amino acids and peptides into liposomes in response to transmembrane pH gradients. , 1992, Biophysical journal.

[18]  M. Bally,et al.  Strategies for Optimizing Liposomal Doxorubicin , 1990 .

[19]  S. Woo,et al.  Liposomal methotrexate in the treatment of murine L1210 leukemia. , 1983, Cancer drug delivery.

[20]  I. Fichtner,et al.  Therapeutic evaluation of liposome-encapsulated Daunoblastin in murine tumor models. , 1981, Neoplasma.